

REMARKS/ARGUMENTS

Claims 7-9 and 14-19 are active. Claims 10 and 20 have been cancelled. Non-elected claims 4-6 and 13 were previously withdrawn from consideration and have now been cancelled without prejudice to representation in a Divisional Application. Claims 7-9 and 14 have been amended as requested by the Examiner to refer to: “brain-derived neurotrophic factor (BDNF)”. Claims 17 and 18 have been amended for clarity. The Applicants thank Examiner Hayes for indicating on March 23, 2009 that the amendments above would likely place this application in condition for allowance. As requested, a formal Amendment making these changes is herewith submitted. Additional editorial changes to further clarify the claim language in claims 7, 9 and 18 prior to allowance were proposed by Examiner Hayes on April 20, 2009. These edits are incorporated into this Amendment. Favorable consideration of this Amendment and an early indication of allowance is respectfully requested.

Restriction/Election

The Applicants previously elected with traverse **Group II**, claims 7-10, directed to methods of detection. The requirement has been made FINAL.

Rejection—35 U.S.C. §112, first paragraph

Claims 7-10 and 14-20 were rejected under 35 U.S.C. 112, first paragraph, as lacking adequate written description. This rejection is moot in view of the adoption of the alternatively claim terminology suggested by the Examiner: “brain-derived neurotrophic factor (BDNF)”. Accordingly, this rejection may now be withdrawn.

Rejections—35 U.S.C. §112, first paragraph

Claims 10; and 10 and 20 were rejected under 35 U.S.C. 112, first paragraph. These rejections are moot in view of the cancellation of these claims.

Rejection—35 U.S.C. §112, second paragraph

Claim 10 was rejected under 35 U.S.C. 112, second paragraph. This rejection is moot in view of the cancellation of claim 10.

Rejection—35 U.S.C. §112, second paragraph


Claims 17 and 18 were rejected under 35 U.S.C. 112, second paragraph. This rejection is moot in view of the amendment of these claims.

Conclusion

This application presents allowable subject matter and the Examiner is respectfully requested to pass it to issue. The Examiner is kindly invited to contact the undersigned should a further discussion of the issues or claims be helpful.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon


Thomas M. Cunningham, Ph.D.
Registration No. 45,394

Customer Number
22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 08/07)